ClinicalTrials.gg
CompletedNCT06646744PEDIVACOV-HCSCUpdated Oct 17, 2024

Safety Study About the mRNA Vaccines Against COVID-19 in Children (PEDIVACOV-HCSC)

An observational study in COVID-19 Vaccine Adverse Reaction, sponsored by Ana Belen Rivas Paterna. Completed at 1 site in Spain. Open to participants aged 5 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Ana Belen Rivas Paterna · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
2,100
Ages
5 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Drug-Related Side Effects and Adverse Reactions with a site in Spain — 6 open to participants now, 8 under way, none of them phase 3. Drug-Related Side Effects and Adverse Reactions · Spain.

Started
2022
with 3 others
Observational
5 of 16
2 open now
Registered
10th of 16
by date
Lead sponsor
1 of 16
Ana Belen Rivas Paterna

Among the 16 studies in Drug-Related Side Effects and Adverse Reactions with a site in Spain, this one is one of 4 that started in 2022, is one of 5 observational ones, and was the 10th registered.

Drug-Related Side Effects and Adverse Reactions

449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.

Browse Drug-Related Side Effects and Adverse Reactions studies →

Open to participants now

6 of the 16 studies in Drug-Related Side Effects and Adverse Reactions with a site in Spain are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 56 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 38 (68%) set no upper age limit and 15 (27%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 5 Years to 12 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Drug-Related Side Effects and Adverse Reactions with a site in Spain, or all of them as a file.
02

Study summary

Drugs side effects in children need to be evaluated in a different way because of their constant growth and body changes.

The use of COVID-19 vaccines (mRNA vaccines) is worldwide spread as a safety measure against the pandemic.

Although clinical trials have shown that vaccines are safe in the general population, specific real-life monitoring is needed to address the special situation that applies to children.

Read the detailed description

Drug-related side effects are an important health problem causing an increase in health costs. Most of the related research is focused on the adult population, therefore evidence in pediatric patients is scarse. This situation remains true in the clinical trials of the mRNA vaccines against COVID-19, with most studies suggesting the need of a greater follow up and specific research that address the pediatric population. Even though vaccines seem to be a safe and effective ways to protect the population against the COVID-19 pandemic, more information is needed regarding the safety profile for pediatrics in the short and long term.

03

Conditions studied

  • COVID-19 Vaccine Adverse Reaction

Keywords

  • COVID19 vaccine
  • Pharmacovigilance
  • Drug-Related Side Effects and Adverse Reactions
04

Who can participate

Ages eligible
5 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All the pediatric patients (between 5-12 years old) vaccinated in the Clinico San Carlos' Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both sexes between 5 and 12 years old.
  • Pediatric patients with data included in the Clinico San Carlos' Hospital available for consultation.
  • Acceptance by the parents/legal guardians for the participation and follow up.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
2,100 participants (actual)
Patient registry
No

Groups and cohorts

  • Vaccinated children

    Children between 5 and 12 years old vaccinated with 2 doses of an approved mRNA vaccione against COVID-19.

    Biological: mRNA COVID-19 vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of vaccine side effects

    Incidence of vaccine side effects

    Time frame: 10 days, 1 month and 6 months after vaccination

Secondary outcomes

  1. Vaccine side effects

    Clinical description of side effects that occurre during follow up

    Time frame: 10 days, 1 month and 6 months after vaccination

  2. Time to vaccine side effect

    Clinical description of side effect according to the time of appearance

    Time frame: 10 days, 1 month and 6 months after vaccination

  3. Causality of side effects

    Evaluation of the causality by using the modified Karch-Lasagna modified scale

    Time frame: 10 days, 1 month and 6 months after vaccination

  4. Severity of side effects

    Evaluation of the severity using de Venulet criteria and the spanish pharmacovigilance system

    Time frame: 10 days, 1 month and 6 months after vaccination

  5. Vaccine and drug interactions

    Evaluation of the possible interaction between the vaccines and regularly prescribed drugs

    Time frame: 10 days, 1 month and 6 months after vaccination

  6. Vaccine reactogenicity

    Evaluation of the difference reactogenicity between the first and second vaccine dose by recording the side effect appearance after each dose.

    Time frame: 10 days, 1 month and 6 months after vaccination

  7. Perceived quality of the vaccination system

    Evaluation of the parents perceived quality of the vaccination system

    Time frame: 10 days, 1 month and 6 months after vaccination

07

Study locations

1 site
  • Fundacion para Investigación Biomedica Hospital Clinico San Carlos
    Madrid, 28040, Spain
08

References and documents

Publications

  • Galindo R, Chow H, Rongkavilit C. COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am. 2021 Oct;68(5):961-976. doi: 10.1016/j.pcl.2021.05.004. Epub 2021 May 18. PubMed 34538306 ↗
  • Belen Rivas A, Arruza L, Pacheco E, Portoles A, Diz J, Vargas E. Adverse drug reactions in neonates: a prospective study. Arch Dis Child. 2016 Apr;101(4):371-6. doi: 10.1136/archdischild-2015-309396. Epub 2016 Jan 27. PubMed 26819267 ↗
  • Vargas E, Terleira A, Hernando F, Perez E, Cordon C, Moreno A, Portoles A. Effect of adverse drug reactions on length of stay in surgical intensive care units. Crit Care Med. 2003 Mar;31(3):694-8. doi: 10.1097/01.CCM.0000049947.80131.ED. PubMed 12626971 ↗
  • Omer SB, Benjamin RM, Brewer NT, Buttenheim AM, Callaghan T, Caplan A, Carpiano RM, Clinton C, DiResta R, Elharake JA, Flowers LC, Galvani AP, Lakshmanan R, Maldonado YA, McFadden SM, Mello MM, Opel DJ, Reiss DR, Salmon DA, Schwartz JL, Sharfstein JM, Hotez PJ. Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet. 2021 Dec 11;398(10317):2186-2192. doi: 10.1016/S0140-6736(21)02507-1. Epub 2021 Nov 15. PubMed 34793741 ↗
  • Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, Ferrajolo C, Moretti U, Poluzzi E, Raschi E, Ravaldi C, Reno C, Tuccori M, Vannacci A, Zanoni G, Trifiro G; Ilmiovaccino COVID19 collaborating group. COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. Drug Saf. 2021 Dec;44(12):1247-1269. doi: 10.1007/s40264-021-01131-6. Epub 2021 Nov 5. PubMed 34739716 ↗
  • Yan Z, Yang M, Lai CL. COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. Vaccines (Basel). 2021 Sep 28;9(10):1097. doi: 10.3390/vaccines9101097. PubMed 34696205 ↗
  • Zheng YJ, Wang XC, Feng LZ, Xie ZD, Jiang Y, Lu G, Li XW, Jiang RM, Deng JK, Liu M, Xu BP, Wei Z, Liu G, Lu XX, Jin RM, Liu ZS, Shang YX, Shu SN, Bai Y, Lu M, Liu GH, Luo WJ, Cui YX, Ye LP, Lin LK, Zhao DC, Shen AD, Shao JB, Xiong LJ, Gao LW, Wang TY; China National Clinical Research Center for Respiratory Diseases; National Center for Children's Health, Beijing, China; Group of Respirology, Chinese Pediatric Society, Chinese Medical Association; Chinese Medical Doctor Association Committee on Respirology Pediatrics; China Medicine Education Association Committee on Pediatrics; Chinese Research Hospital Association Committee on Pediatrics; Chinese Non-government Medical Institutions Association Committee on Pediatrics; China Association of Traditional Chinese Medicine, Committee on Children's Health and Medicine Research; Zhao ZY, Yang YH, Shen KL. Expert consensus on COVID-19 vaccination in children. World J Pediatr. 2021 Oct;17(5):449-457. doi: 10.1007/s12519-021-00465-6. Epub 2021 Oct 7. No abstract available. PubMed 34618327 ↗

Individual participant data

Plan to share: No — There is not a plan to make IPD available

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Mar 2023, 11 months.

Of 65 non-industry observational studies under Drug-Related Side Effects and Adverse Reactions, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24. This study's 11 months is below that.

Counting every sponsor, half of 69 studies reached it within 45 months; a quarter within 24 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 17, 2024
StartActual
Mar 8, 2022
Primary completionActual
Mar 3, 2023
CompletionActual
Mar 3, 2023
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06646744
Lead sponsor
Ana Belen Rivas Paterna
Responsible party
Ana Belen Rivas Paterna (designed by Principal Investigator, Hospital San Carlos, Madrid) — Sponsor-investigator
First posted
Oct 17, 2024
Start date
Mar 8, 2022
Primary completion
Mar 3, 2023
Completion
Mar 3, 2023
Last update
Oct 17, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion